Cargando…

Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data

OBJECTIVES: To describe the prevalence of multimorbidity (presence of two or more long-term health conditions) in the New Zealand (NZ) population, and compare risk of health outcomes by multimorbidity status. DESIGN: Cross-sectional analysis for prevalence of multimorbidity, with 1-year prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanley, James, Semper, Kelly, Millar, Elinor, Sarfati, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988147/
https://www.ncbi.nlm.nih.gov/pubmed/29794103
http://dx.doi.org/10.1136/bmjopen-2018-021689
_version_ 1783329240237735936
author Stanley, James
Semper, Kelly
Millar, Elinor
Sarfati, Diana
author_facet Stanley, James
Semper, Kelly
Millar, Elinor
Sarfati, Diana
author_sort Stanley, James
collection PubMed
description OBJECTIVES: To describe the prevalence of multimorbidity (presence of two or more long-term health conditions) in the New Zealand (NZ) population, and compare risk of health outcomes by multimorbidity status. DESIGN: Cross-sectional analysis for prevalence of multimorbidity, with 1-year prospective follow-up for health outcomes. SETTING: NZ general population using national-level routine health data on hospital discharges and pharmaceutical dispensing. PARTICIPANTS: All NZ adults (aged 18+, n=3 489 747) with an active National Health Index number at the index date (1 January 2014). OUTCOME MEASURES: Prevalence of multimorbidity was calculated using two data sources: prior routine hospital discharge data (61 ICD-10 coded diagnoses from the M3 multimorbidity index); and recent pharmaceutical dispensing records (30 conditions from the P3 multimorbidity index). METHODS: Prevalence of multimorbidity was calculated separately for the two data sources, stratified by age group, sex, ethnicity and socioeconomic deprivation, and age and sex standardised to the total population. One-year risk of poor health outcomes (mortality, ambulatory sensitive hospitalisation (ASH) and overnight hospital admission) was compared by multimorbidity status using logistic regression adjusted for confounders. RESULTS: Prevalence of multimorbidity was 7.9% using past hospital discharge data, and 27.9% using past pharmaceutical dispensing data. Prevalence increased with age, with a clear socioeconomic gradient and differences in prevalence by ethnicity. Age and sex standardised risk of 1-year mortality was 2.7% for those with multimorbidity (defined on hospital discharge data), and 0.5% for those without multimorbidity (age and sex-adjusted OR 4.8, 95% CI 4.7 to 5.0). Risk of ASH was also increased for those with multimorbidity (eg, pharmaceutical discharge definition: age and sex-standardised risk 6.2%, compared with 1.8% for those without multimorbidity; age and sex-adjusted OR 3.6, 95% CI 3.5 to 3.6). CONCLUSIONS: Multimorbidity is common in the NZ adult population, with disparities in who is affected. Providing for the needs of individuals with multimorbidity requires collaborative and coordinated work across the health sector.
format Online
Article
Text
id pubmed-5988147
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-59881472018-06-07 Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data Stanley, James Semper, Kelly Millar, Elinor Sarfati, Diana BMJ Open Epidemiology OBJECTIVES: To describe the prevalence of multimorbidity (presence of two or more long-term health conditions) in the New Zealand (NZ) population, and compare risk of health outcomes by multimorbidity status. DESIGN: Cross-sectional analysis for prevalence of multimorbidity, with 1-year prospective follow-up for health outcomes. SETTING: NZ general population using national-level routine health data on hospital discharges and pharmaceutical dispensing. PARTICIPANTS: All NZ adults (aged 18+, n=3 489 747) with an active National Health Index number at the index date (1 January 2014). OUTCOME MEASURES: Prevalence of multimorbidity was calculated using two data sources: prior routine hospital discharge data (61 ICD-10 coded diagnoses from the M3 multimorbidity index); and recent pharmaceutical dispensing records (30 conditions from the P3 multimorbidity index). METHODS: Prevalence of multimorbidity was calculated separately for the two data sources, stratified by age group, sex, ethnicity and socioeconomic deprivation, and age and sex standardised to the total population. One-year risk of poor health outcomes (mortality, ambulatory sensitive hospitalisation (ASH) and overnight hospital admission) was compared by multimorbidity status using logistic regression adjusted for confounders. RESULTS: Prevalence of multimorbidity was 7.9% using past hospital discharge data, and 27.9% using past pharmaceutical dispensing data. Prevalence increased with age, with a clear socioeconomic gradient and differences in prevalence by ethnicity. Age and sex standardised risk of 1-year mortality was 2.7% for those with multimorbidity (defined on hospital discharge data), and 0.5% for those without multimorbidity (age and sex-adjusted OR 4.8, 95% CI 4.7 to 5.0). Risk of ASH was also increased for those with multimorbidity (eg, pharmaceutical discharge definition: age and sex-standardised risk 6.2%, compared with 1.8% for those without multimorbidity; age and sex-adjusted OR 3.6, 95% CI 3.5 to 3.6). CONCLUSIONS: Multimorbidity is common in the NZ adult population, with disparities in who is affected. Providing for the needs of individuals with multimorbidity requires collaborative and coordinated work across the health sector. BMJ Publishing Group 2018-05-24 /pmc/articles/PMC5988147/ /pubmed/29794103 http://dx.doi.org/10.1136/bmjopen-2018-021689 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
Stanley, James
Semper, Kelly
Millar, Elinor
Sarfati, Diana
Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title_full Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title_fullStr Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title_full_unstemmed Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title_short Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data
title_sort epidemiology of multimorbidity in new zealand: a cross-sectional study using national-level hospital and pharmaceutical data
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988147/
https://www.ncbi.nlm.nih.gov/pubmed/29794103
http://dx.doi.org/10.1136/bmjopen-2018-021689
work_keys_str_mv AT stanleyjames epidemiologyofmultimorbidityinnewzealandacrosssectionalstudyusingnationallevelhospitalandpharmaceuticaldata
AT semperkelly epidemiologyofmultimorbidityinnewzealandacrosssectionalstudyusingnationallevelhospitalandpharmaceuticaldata
AT millarelinor epidemiologyofmultimorbidityinnewzealandacrosssectionalstudyusingnationallevelhospitalandpharmaceuticaldata
AT sarfatidiana epidemiologyofmultimorbidityinnewzealandacrosssectionalstudyusingnationallevelhospitalandpharmaceuticaldata